Patient Derived Xenografts/PDX Models Market

The PDx models market is projected to grow from USD 0.37 billion in 2025 to USD 0.66 billion in 2030, at a CAGR of 12.5% during the forecast period. The market is driven by the growing demand for personalized medicine, rising investments in cancer research, and continuous technological advancements in the development of PDx models. The increasing prevalence of cancer and the need for predictive, patient-relevant preclinical systems are driving the adoption of these systems across the pharmaceutical, biotechnology, and academic sectors, enabling more precise drug discovery, biomarker validation, and translational oncology research.

The market is consolidated. The prominent players operating in this market include The Jackson Laboratory (US), Charles River Laboratories (US), Inotiv (US), JSR Corporation (Japan), WuXi AppTec (China), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv (US), Pharmatest Services (Finland), and Hera Biolabs (US), among others. These market players have implemented various strategies, including product launches, acquisitions, collaborations, and expansions, to strengthen their market positions in PDx Models.

To know about the assumptions considered for the study download the pdf brochure

In April 2025, Charles River Laboratories (US) announced updates to its comprehensive portfolio of products and services, which support the discovery and development of novel oncology drugs. The company has developed PDx-derived models. The company is also exploring alternatives, such as organoids, also known as tumoroids, which are self-organized 3D cell cultures designed to mimic the structure, function, and cellular complexity of human organs.

Charles River Laboratories (US)

Charles River offers one of the industry’s largest fully characterized PDx portfolios, spanning major tumor histotypes and supported by searchable tumor-model databases and standardized study packages (including subcutaneous, orthotopic, and I/O readouts). CRL also validates humanized-immune PDx (HSC/PBMC) to run checkpoint/bispecific and cell-therapy studies, which is a key differentiator as sponsors shift to immuno-oncology combinations. Strategically, CRL has combined organic build-out with targeted M&A: the acquisition of Oncotest GmbH (2015) brought a deep European PDx franchise and know-how in orthotopic/PDOX and ex vivo assays, accelerating CRL’s panel growth and clinical annotation depth. More recently, CRL partnered with Aitia to integrate AI “digital twins” with PDx workflows (LOGICA platform), aiming to improve candidate selection and responder enrichment—an example of CRL fusing wet-lab scale with computational prediction.

The Jackson Laboratory (US)

JAX operates a PDx Tumor Model Repository with hundreds of clinically annotated models available, either as contracted in vivo studies or distributed biospecimens. The resource is tightly integrated with the MMHCdb/PDx database, enabling selection by primary site, genotype, and prior dosing outcomes—a distinctive “data-first” entry point for sponsors. JAX’s long leadership in NSG immunodeficient strains and humanized systems supports both conventional PDx efficacy and I/O-enabled studies. Beyond commercial services, JAX plays a visible role in community initiatives (e.g., PDxNet), contributing models, sequencing, and metadata standardization—features that are useful for sponsors who value open, comparable datasets and published methods.

Market Ranking

The market is characterized by significant competition, with the leading players capturing approximately 60-65% of the total market share. CRL holds a prominent position, driven by its comprehensive portfolio encompassing. The company’s focus on developing next-generation models for enhancing drug discovery & development of innovative medicines is a key contributor to its dominant position. The JAX Laboratory and Inotiv also command substantial market shares through continuous investment in R&D aimed at launching new PDx models and introducing new service capabilities.

The emerging growth potential in the Asia Pacific region offers opportunities for companies to expand their presence amid rising drug discovery & research activities. Regional and emerging players account for the remaining 35-40% of the market share, leading to notable consolidation within the sector.

The prominent players operating in this market include The Jackson Laboratory (US), Charles River Laboratories (US), Inotiv (US), JSR Corporation (Japan), WuXi AppTec (China), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv (US), Pharmatest Services (Finland), and Hera Biolabs (US), among others. These market players have implemented various strategies, including product launches, acquisitions, collaborations, and expansions, to strengthen their market positions in PDx models.

Related Reports:

Patient Derived Xenografts/PDX Models Market by Type (Mouse, Rat), Service (Model Creation, Characterization), Implantation Method (Subcutaneous), Tumor Type (Respiratory, GI, Gynecological), Application (Preclinical, Biomarker) - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com